Breast cancer patients indeed had a significant lower percentage of CD119+ Lin-/HLA-DR+ DCs compared with healthy controls (82.00 ± 3.63 of the DCs vs 89.92 ± 1.85%; P=0.05). This evidence concerns the gene IFNGR1 and breast cancer.